Share price · CGEN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+9.2%
- 22 Oct 2026-7.5%
Nothing announced by CGEN that day or the session before.
- 25 Aug 2026+10.8%
Nothing announced by CGEN that day or the session before.
- 20 Aug 2026+8.6%
Nothing announced by CGEN that day or the session before.
- 2 Mar 2026+24.3%
- 20 Jan 2026-7.6%
Nothing announced by CGEN that day or the session before.
- 16 Jan 2026+11.8%
Nothing announced by CGEN that day or the session before.
- 15 Jan 2026+6.6%
Nothing announced by CGEN that day or the session before.
- 9 Jan 2026+14.6%
Nothing announced by CGEN that day or the session before.
Share of unusual movement by asset
For each asset, the share of CGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 86% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1 and TIGITMultispecific antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaBiliary Tract CancerGastric CancerBladder / Urothelial CancerEndometrial Cancer Urothelial Carcinoma | |
| Phase 1/2 | PVRIG (CD112R)Monoclonal antibody | Ovarian Cancer | |
| Phase 1 | TIGITMonoclonal antibody | Multiple Myeloma |
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
March 2027 (1)
May 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (2)
2029 (10)
January 2029 (2)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
April 2029 (2)
July 2029 (1)
What to watch
August 2029 (1)
What to watch
October 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (6)
January 2030 (1)
What to watch
March 2030 (1)
What to watch
May 2030 (1)
What to watch
July 2030 (1)
What to watch
September 2030 (1)
What to watch
November 2030 (1)
What to watch
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $73M | $23M | $91M+ $9.3M short-term inv. | —$32M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $28M | $25M | $18M+ $24M short-term inv. | $3.6M$50M operating cash flow | report ↗ |
| 2023-FY | $33M | $34M | $14M+ $12M short-term inv. | $4.7M-$36M operating cash flow | report ↗ |
| 2022-FY | $7.5M | $31M | $11M+ $0 short-term inv. | $8.4M-$35M operating cash flow | report ↗ |
| 2021-FY | $6.0M | $29M | $8.5M+ $109M short-term inv. | $8.6M-$23M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($126K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-29 | Mahler Michelle · Chief Medical Officer | Award / grant | 13,500 | — | — | Form 4 |
| 2026-07-29 | ZWEIFACH SANFORD S · director | Award / grant | 7,500 | — | — | Form 4 |
| 2026-07-29 | Halevy Gilead · director | Award / grant | 7,500 | — | — | Form 4 |
| 2026-07-29 | Hukkelhoven Mathias · director | Award / grant | 7,500 | — | — | Form 4 |
| 2026-07-29 | Livnat Savitzky Kinneret · director | Award / grant | 7,500 | — | — | Form 4 |
| 2026-07-29 | Kredo Russo Sharon · SVP, Research & Discovery | Award / grant | 18,000 | — | — | Form 4 |
| 2026-07-29 | Ferre Pierre · Chief Operating Officer | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-07-29 | Perry Eran · director | Award / grant | 7,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 14.2M shares ($30.7M, 15.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SILVERARC CAPITAL MANAGEMENT, LLC | 3,315,845 | $7.1M |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,632,988 | $3.5M |
| 3 | MORGAN STANLEY | 1,053,229 | $2.2M |
| 4 | ARK Investment Management LLC | 1,049,873 | $2.2M |
| 5 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1,020,000 | $2.2M |
| 6 | Taylor Frigon Capital Management LLC | 848,043 | $1.8M |
| 7 | NORTHERN TRUST CORP | 650,868 | $1.4M |
| 8 | TWO SIGMA INVESTMENTS, LP | 521,587 | $1.1M |
| 9 | STATE STREET CORP | 415,366 | $885K |
| 10 | Yelin Lapidot Holdings Management Ltd. | 318,852 | $679K |
| 11 | UBS Group AG | 306,708 | $653K |
| 12 | WELLS FARGO & COMPANY/MN | 3,100 | $646K |
| 13 | DAFNA Capital Management LLC | 257,783 | $549K |
| 14 | MARSHALL WACE, LLP | 244,480 | $521K |
| 15 | MILLENNIUM MANAGEMENT LLC | 168,927 | $360K |